Your browser doesn't support javascript.
loading
The current state of molecular testing in the treatment of patients with solid tumors, 2019.
El-Deiry, Wafik S; Goldberg, Richard M; Lenz, Heinz-Josef; Shields, Anthony F; Gibney, Geoffrey T; Tan, Antoinette R; Brown, Jubilee; Eisenberg, Burton; Heath, Elisabeth I; Phuphanich, Surasak; Kim, Edward; Brenner, Andrew J; Marshall, John L.
Afiliação
  • El-Deiry WS; Associate Dean for Oncologic Sciences, Warren Alpert Medical School; Director, Joint Program in Cancer Biology, Brown University and the Lifespan Cancer Institute; Professor of Pathology & Laboratory Medicine and Professor of Medical Science, Brown University, Providence, RI.
  • Goldberg RM; Professor of Medicine and Director, West Virginia University Cancer Institute, Morgantown, WV.
  • Lenz HJ; Professor of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
  • Shields AF; Professor of Oncology, Karmanos Cancer Institute, Detroit, MI.
  • Gibney GT; Associate Professor of Medicine, Co-Leader of the Melanoma Disease Group, Lombardi Comprehensive Cancer Institute, MedStar Georgetown Cancer Institute, Washington, DC.
  • Tan AR; Co-Director of Phase I Program, Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • Brown J; Professor and Associate Director of Gynecologic Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • Eisenberg B; Professor of Clinical Surgery, University of Southern California, Los Angeles, CA.
  • Heath EI; Executive Medical Director, Hoag Family Cancer Institute, Newport Beach, CA.
  • Phuphanich S; Professor of Oncology and Medicine, Karmanos Cancer Institute, Detroit, MI.
  • Kim E; Professor of Neurology, Director, Division of Neuro-Oncology, Barrow Neurological Institute, Phoenix, AZ.
  • Brenner AJ; Chair, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • Marshall JL; Associate Professor of Medicine, Mays Cancer Center at , University of Texas Health San Antonio Cancer Center, San Antonio, TX.
CA Cancer J Clin ; 69(4): 305-343, 2019 07.
Article em En | MEDLINE | ID: mdl-31116423
The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor site of origin. Molecular profiling methodologies have likewise changed such that tests that were performed on patients a few years ago are no longer complete and possibly inaccurate today. As with all rapid change, medical providers can quickly fall behind or struggle to find up-to-date sources to ensure he or she provides optimum care. In this review, the authors provide the current state of the art for molecular profiling/precision medicine, practice standards, and a view into the future ahead.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas Genéticas / Medicina de Precisão / Neoplasias Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas Genéticas / Medicina de Precisão / Neoplasias Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article